兽用整形外科药物市场－全球产业规模、份额、趋势、机会、预测：按产品类型、动物类型、给药途径、最终用途、地区和竞争格局划分，2021-2031年

全球兽用整形外科药物市场预计将从 2025 年的 42.3 亿美元成长到 2031 年的 66.8 亿美元，复合年增长率为 7.91%。

该领域涵盖动物肌肉骨骼问题的外科和药物治疗，重点在于骨折修復、关节疾病治疗和韧带损伤癒合，旨在减轻疼痛并恢復运动功能。推动这一领域发展的主要因素是宠物人性化的趋势日益增强。将宠物视为家庭成员的饲主往往更积极地投入资金进行復健治疗。此外，老年宠物肥胖率的上升也增加了对骨关节炎和其他退化性关节疾病的医疗干预需求。

儘管有这些积极迹象，但复杂手术和术后復原的高昂费用仍然是市场成长的主要障碍。这些高昂的费用往往使预算有限或没有保险的宠物饲主难以负担专业的整形外科治疗。根据美国宠物用品协会（APPA）的数据，2024年犬饲主在外科兽医护理方面的平均年度支出为458美元。这项统计数据凸显了经济障碍的存在，这些障碍限制了宠物获得昂贵的整形外科手术的机会，并可能阻碍整个市场的扩张。

市场驱动因素

宠物健康保险的快速成长是全球兽用整形外科药物市场的主要驱动力，因为它降低了复杂外科手术的经济门槛。由于全髋关节置换术和胫骨平台水平截骨术（TPLO）等治疗费用昂贵，保险提供了一张至关重要的安全网，使饲主能够核准治疗，而不是选择安乐死或保守治疗。根据北美宠物健康保险协会（NAPHIA）2024年5月发布的产业趋势报告，2023年北美地区的保费总额达到42.7亿美元。这种经济支持使兽医能够提案建议的治疗方案，而不会因为费用问题而立即被拒绝。同时，英国保险协会（ABI）报告称，2024年的赔偿额将达到创纪录的10亿英镑，这表明有充足的资金支持专业整形外科中心的发展。

同时，可支配收入的成长和兽医医疗费用支出的增加刺激了对先进肌肉骨骼治疗的需求，从而推动了市场成长。宠物饲主越来越重视爱犬的寿命和健康，因此在高品质整形外科植入和专业医疗服务方面的支出也随之增加。这种经济基础为先进生物疗法和个人化解决方案的推广应用创造了有利环境。根据美国宠物用品协会 (APPA) 2024 年 3 月发布的《产业趋势》报告，2023 年美国宠物产业总支出达 1,470 亿美元。这笔资金的流入使兽医院能够投资先进的诊断设备和仪器，提高其处理复杂整形外科病例的能力，并带动药品和医疗设备市场的扩张。

市场挑战

先进的外科手术和术后復健的高昂费用是全球兽用整形外科药物市场的主要障碍。这些高昂的治疗费用构成了巨大的经济负担，迫使饲主选择费用较低的安宁疗护。面对昂贵的重建手术和保守治疗之间的选择，预算紧张的饲主往往会放弃专业的治疗。这种经济上的犹豫直接导致手术数量的减少，从而限制了手术器械和整形外科植入製造商的商机。

兽医费用的急剧上涨进一步加剧了这一困境，其涨幅往往超过整体通货膨胀率，并扩大了经济负担。英国保险协会在2024年报告称，宠物保险的平均理赔金额已升至685英镑，而复杂的整形外科治疗，例如肘关节发育不良，费用可能高达5万英镑。如此高昂的费用凸显了未投保宠物饲主面临的严重财务风险。因此，整形外科解决方案的市场仅限于小规模的客户群，例如用户和富裕人士，这实际上限制了该行业进一步扩张的潜力。

市场趋势

单株抗体（mAb）疗法的广泛应用正在改变兽医整形外科疼痛管理方式，它提供了一种靶向性强、每月一次的治疗方案，可取代每日非类固醇消炎剂。与可能导致肝肾毒性的传统药物不同，这些生物製药特异性抑制神经生长因子，从而缓解骨关节炎疼痛，并显着提高安全性。随着兽医在长期慢性病治疗中越来越倾向于使用这些注射剂而非标准口服药物，向物种特异性生物製药的技术转型正在为该行业带来可观的收入。在2025年2月发布的2024年度报告中，硕腾公司（Zoetis）公布了93亿美元的总收入，并将这一成功归功于其猫狗骨关节炎疼痛产品在全球范围内的强劲市场需求。

同时，生物製药与再生医学的深度融合正在推进，治疗重点也从症状控制转向结构性组织修復。富血小板血浆（PRP）疗法和异体干细胞疗法的创新，使医疗专业人员能够透过调节发炎和促进软骨再生来治疗退化性关节疾病的根本原因。这一趋势的驱动力在于，各方投入巨资，旨在克服供体获取方面的传统挑战，并实现「即用型」生物製剂的标准化，使其能够广泛应用于临床。例如，根据dvm360报道，Gallant 治疗方法在2025年7月资金筹措，以加速其用于治疗犬猫整形外科疾病的即用型间质干细胞产品的商业化进程。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球兽用整形外科药物市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 产品类型（生物製药、黏弹性替代品、药品）
  • 依动物类型（狗、猫、马、牛、猪、其他）
  • 给药途径（口服、注射、局部）
  • 透过申请（兽医医院/诊所、居家医疗环境、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美兽用整形外科药物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲兽用整形外科药物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区兽用整形外科药物市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲兽用整形外科药物市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲兽用整形外科药物市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球兽用整形外科药物市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Enso Discoveries, LLC
• Zoetis, Inc.
• Boehringer Ingelheim International GmbH
• Elanco Animal Health Inc
• Biogenesis Bago SA
• American Regent, Inc..
• Merck & Co., Inc.
• Vetoquinol SA
• Ceva Sante Animale
• Virbac SA

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Veterinary Orthopedic Medicine Market is projected to expand from USD 4.23 Billion in 2025 to USD 6.68 Billion by 2031, reflecting a CAGR of 7.91%. This sector covers the surgical and pharmaceutical management of animal musculoskeletal issues, focusing on repairing fractures, treating joint diseases, and healing ligament injuries to reduce pain and restore movement. A major force behind this growth is the increasing trend of pet humanization, as owners who regard their animals as family members are more inclined to fund restorative treatments. Furthermore, rising obesity rates in aging pets are fueling the need for medical interventions to manage osteoarthritis and other degenerative joint disorders.

Despite these positive indicators, the significant expenses linked to complex surgeries and post-operative rehabilitation pose a major obstacle to market growth. These high costs often make specialized orthopedic care unattainable for pet owners with limited budgets or without insurance. Data from the American Pet Products Association indicates that in 2024, dog owners spent an average of $458 annually on surgical veterinary visits. This statistic underscores the economic hurdles that restrict the uptake of costly orthopedic procedures, potentially limiting the overall reach of the market.

Market Driver

The swift growth of pet health insurance serves as a key driver for the Global Veterinary Orthopedic Medicine Market by reducing financial obstacles to complex surgical procedures. Since interventions like total hip replacements and tibial plateau leveling osteotomy (TPLO) are expensive, insurance coverage offers a vital safety net that encourages owners to approve treatment rather than choosing euthanasia or conservative management. According to the North American Pet Health Insurance Association's May 2024 'State of the Industry Report', total premium volume in North America hit $4.27 billion in 2023. This financial support enables veterinarians to suggest preferred repair options without immediate dismissal due to cost, while the Association of British Insurers reported a record £1 billion in claims paid out in 2024, demonstrating the significant funds supporting specialized orthopedic centers.

Simultaneously, rising disposable income and increased spending on veterinary healthcare are reinforcing market growth by fueling demand for superior musculoskeletal treatments. Pet owners are placing greater importance on their animals' longevity and well-being, resulting in higher spending on premium orthopedic implants and specialized medical services. This economic readiness fosters an environment conducive to advanced biological therapies and customized solutions. The American Pet Products Association's March 2024 'State of the Industry' report noted that total U.S. pet industry expenditures reached $147 billion in 2023. This capital influx allows veterinary clinics to acquire advanced diagnostic tools and instrumentation, improving their ability to manage complex orthopedic cases and expanding the market for pharmaceuticals and medical devices.

Market Challenge

The considerable expense associated with advanced surgeries and post-surgical rehabilitation acts as a major impediment to the global veterinary orthopedic medicine market. High procedural costs establish a formidable economic hurdle, often forcing pet owners to decline necessary surgeries in favor of cheaper, palliative management strategies. When choosing between expensive restorative operations and conservative care, owners with budget constraints frequently refuse specialized treatment. This financial hesitation directly lowers the number of surgeries performed, thereby restricting revenue opportunities for producers of surgical instruments and orthopedic implants.

This difficulty is exacerbated by the rapid rise in veterinary medical costs, which frequently exceed general inflation rates and widen the affordability gap. In 2024, the Association of British Insurers reported that the average pet insurance claim increased to £685, with complex orthopedic treatments for issues like elbow dysplasia costing as much as £50,000. Such high costs highlight the severe financial risk for uninsured pet owners. As a result, the serviceable market for orthopedic solutions is limited to a smaller segment of insured or wealthy clients, effectively capping the industry's potential for broader expansion.

Market Trends

The extensive adoption of monoclonal antibody (mAb) therapies is transforming veterinary orthopedic pain management by providing a targeted, monthly substitute for daily non-steroidal anti-inflammatory drugs. In contrast to traditional medications that may cause hepatic or renal toxicity, these biological agents specifically block nerve growth factor to relieve osteoarthritis pain with a much better safety profile. This technical transition toward species-specific biologics is generating significant industry revenue, as veterinarians increasingly prefer these injectables over standard oral drugs for long-term chronic care. In its February 2025 '2024 Annual Report', Zoetis announced total revenue of $9.3 billion, attributing this success to the strong global adoption of its osteoarthritis pain products for cats and dogs.

At the same time, the market is seeing strong integration of biologics and regenerative medicine, shifting treatment focus from symptom control to structural tissue repair. Innovations in platelet-rich plasma and allogeneic stem cell therapies allow practitioners to treat the underlying causes of degenerative joint diseases by modulating inflammation and stimulating cartilage regeneration. This trend is bolstered by substantial investments designed to standardize these 'off-the-shelf' biological treatments for broad clinical application, overcoming earlier hurdles regarding donor sourcing. For instance, dvm360 reported in July 2025 that Gallant Therapeutics raised $18 million in Series B funding to speed up the commercialization of its ready-to-use mesenchymal stem cell products for canine and feline orthopedic conditions.

Key Market Players

• Enso Discoveries, LLC
• Zoetis, Inc.
• Boehringer Ingelheim International GmbH
• Elanco Animal Health Inc
• Biogenesis Bago SA
• American Regent, Inc..
• Merck & Co., Inc.
• Vetoquinol S.A.
• Ceva Sante Animale
• Virbac S.A.

Report Scope

In this report, the Global Veterinary Orthopedic Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Veterinary Orthopedic Medicine Market, By Product Type

• Biologics
• Viscosupplements
• Pharmaceuticals

Veterinary Orthopedic Medicine Market, By Animal type

• Canine
• Feline
• Equine
• Cattle
• Swine
• Others

Veterinary Orthopedic Medicine Market, By Route of Administration

• Oral
• Parenteral
• Topical

Veterinary Orthopedic Medicine Market, By End Use

• Veterinary Hospitals and Clinics
• Homecare Settings
• Others

Veterinary Orthopedic Medicine Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Orthopedic Medicine Market.

Available Customizations:

Global Veterinary Orthopedic Medicine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Veterinary Orthopedic Medicine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Biologics, Viscosupplements, Pharmaceuticals)
  • 5.2.2. By Animal type (Canine, Feline, Equine, Cattle, Swine, Others)
  • 5.2.3. By Route of Administration (Oral, Parenteral, Topical)
  • 5.2.4. By End Use (Veterinary Hospitals and Clinics, Homecare Settings, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Veterinary Orthopedic Medicine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Animal type
  • 6.2.3. By Route of Administration
  • 6.2.4. By End Use
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Veterinary Orthopedic Medicine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Animal type
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By End Use
  • 6.3.2. Canada Veterinary Orthopedic Medicine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Animal type
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By End Use
  • 6.3.3. Mexico Veterinary Orthopedic Medicine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Animal type
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By End Use

7. Europe Veterinary Orthopedic Medicine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Animal type
  • 7.2.3. By Route of Administration
  • 7.2.4. By End Use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Veterinary Orthopedic Medicine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Animal type
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By End Use
  • 7.3.2. France Veterinary Orthopedic Medicine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Animal type
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By End Use
  • 7.3.3. United Kingdom Veterinary Orthopedic Medicine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Animal type
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By End Use
  • 7.3.4. Italy Veterinary Orthopedic Medicine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Animal type
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By End Use
  • 7.3.5. Spain Veterinary Orthopedic Medicine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Animal type
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By End Use

8. Asia Pacific Veterinary Orthopedic Medicine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Animal type
  • 8.2.3. By Route of Administration
  • 8.2.4. By End Use
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Veterinary Orthopedic Medicine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Animal type
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By End Use
  • 8.3.2. India Veterinary Orthopedic Medicine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Animal type
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By End Use
  • 8.3.3. Japan Veterinary Orthopedic Medicine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Animal type
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By End Use
  • 8.3.4. South Korea Veterinary Orthopedic Medicine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Animal type
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By End Use
  • 8.3.5. Australia Veterinary Orthopedic Medicine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Animal type
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By End Use

9. Middle East & Africa Veterinary Orthopedic Medicine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Animal type
  • 9.2.3. By Route of Administration
  • 9.2.4. By End Use
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Veterinary Orthopedic Medicine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Animal type
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By End Use
  • 9.3.2. UAE Veterinary Orthopedic Medicine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Animal type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By End Use
  • 9.3.3. South Africa Veterinary Orthopedic Medicine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Animal type
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By End Use

10. South America Veterinary Orthopedic Medicine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Animal type
  • 10.2.3. By Route of Administration
  • 10.2.4. By End Use
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Veterinary Orthopedic Medicine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Animal type
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By End Use
  • 10.3.2. Colombia Veterinary Orthopedic Medicine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Animal type
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By End Use
  • 10.3.3. Argentina Veterinary Orthopedic Medicine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Animal type
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Veterinary Orthopedic Medicine Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Enso Discoveries, LLC
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Zoetis, Inc.
• 15.3. Boehringer Ingelheim International GmbH
• 15.4. Elanco Animal Health Inc
• 15.5. Biogenesis Bago SA
• 15.6. American Regent, Inc..
• 15.7. Merck & Co., Inc.
• 15.8. Vetoquinol S.A.
• 15.9. Ceva Sante Animale
• 15.10. Virbac S.A.

16. Strategic Recommendations

17. About Us & Disclaimer